Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.

# Inimmune

Harnessing the Immune System to Improve Human Health

## Sitemaps

- [XML Sitemap](https://inimmune.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Characterization of a transmembrane-activating STING agonist using genetically humanized mice](https://inimmune.com/characterization-of-a-transmembrane-activating-sting-agonist-using-genetically-humanized-mice/)
- [Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients](https://inimmune.com/inimmune-commences-pivotal-phase-2-allergy-trial-of-ini-2004-in-allergic-rhinitis-patients/) - Missoula, Montana – January 7, 2026 – Inimmune Corporation (“Inimmune”), a clinical-stage biotechnology company focused on developing innovative immunotherapies, today announced the start of its pivotal Phase 2 clinical trial evaluating INI-2004 in patients with allergic rhinitis. The Phase 2 study is a randomized, double blind, placebo-controlled allergen chamber trial being conducted in Kingston, Ontario,
- [Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout](https://inimmune.com/inimmune-strengthens-leadership-team-ahead-of-phase-2-ini-2004-allergic-rhinitis-data-readout/) - Ferdinand Massari, M.D., appointed Chief Medical Officer to lead clinical strategy and pipeline advancement Ryan McMillian named Head of Financial Strategy to support corporate strategy and long-term growth Missoula, MT – March 5, 2026 – Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical
- [Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis](https://inimmune.com/inimmune-completes-enrollment-and-doses-first-patient-in-phase-2-chamber-trial-of-ini-2004-for-allergic-rhinitis/) - INI-2004 advances as a rapid, disease-modifying immunotherapy for allergic rhinitis with platform potential across all allergic diseases; topline data expected June 2026 Missoula, MT — March 11, 2026 — Inimmune Corporation, a clinical-stage biotechnology company developing novel immunotherapies for allergic diseases, today announced the completion of enrollment and dosing of the first patient in its
- [Inimmune to Showcase Pipeline Advances at World Vaccine Congress 2026](https://inimmune.com/inimmune-to-showcase-pipeline-advances-at-world-vaccine-congress-2026/) - Missoula, MT — March 29, 2026 — Inimmune, a biotechnology company advancing next-generation vaccine adjuvants and immunotherapies, today announced that its leadership team will present new data and insights at the World Vaccine Congress (WVC) in Washington, DC, from March 30 to April 2, 2026. CEO David Burkhart, Ph.D., will chair the “Vaccine Technology Workshop”
- [Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004](https://inimmune.com/inimmune-announces-successful-phase-1-clinical-results-for-disease-modifying-allergy-treatment-ini-2004/) - MISSOULA, Montana, May 15, 2024 – Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis (NCT06038279). In response to ragweed challenge, participants
- [Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st](https://inimmune.com/inimmune-to-present-an-update-on-clinical-stage-vaccine-adjuvant-and-immunotherapy-programs-at-the-world-vaccine-congress-in-washington-dc-on-april-1st/) - MISSOULA, Montana, April 1, 2024 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will present a talk titled ” Alternative uses for adjuvants & cross-over immunotherapy technologies” at the World Vaccine Congress, in Washington
- [Inimmune to Present at the Medinvest Oncology Conference on INI-4001](https://inimmune.com/inimmune-to-present-at-the-medinvest-oncology-conference-on-ini-4001/)
- [Promotion of Th17 polarized immunity via co-delivery of Mincle agonist and Tuberculosis antigen using silica nanoparticles](https://inimmune.com/promotion-of-th17-polarized-immunity-via-co-delivery-of-mincle-agonist-and-tuberculosis-antigen-using-silica-nanoparticles/)
- [Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses](https://inimmune.com/vaccination-with-mincle-agonist-um-1098-and-mycobacterial-antigens-induces-protective-th1-and-th17-responses/)
- [SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems](https://inimmune.com/spi-pharma-inc-and-inimmune-corp-partner-to-develop-and-commercialize-innovative-vaccine-adjuvant-systems/) - MISSOULA, Montana, July 16, 2024 – SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development.
- [Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist](https://inimmune.com/inimmune-announces-first-cancer-patient-dosed-in-phase-1-clinical-study-using-the-immunotherapeutic-ini-4001-a-novel-tlr7-8-agonist/) - MISSOULA, Montana, July 24, 2024 - Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with advanced solid tumors. This is an open-label, multiple-ascending dose, two-part dose
- [Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1](https://inimmune.com/vaccination-with-ancestral-sars-cov-2-spike-adjuvanted-with-tlr-agonists-provides-cross-protection-against-xbb-1/)
- [Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery](https://inimmune.com/insilico-medicine-and-inimmune-achieved-collaboration-to-revolutionize-immunotherapy-with-ai-driven-drug-discovery/) - Cambridge, Mass, September 13, 2024 – Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics. Chemistry42, a multi-agent reinforcement learning system designed
- [SPI Pharma, Inc. and Inimmune, Corp. Launch Partnership to Commercialize Advanced Adjuvant Systems](https://inimmune.com/spi-pharma-inc-and-inimmune-corp-launch-partnership-to-commercialize-advanced-adjuvant-systems/) - Wilmington, Delaware, October 22, 2024 - SPI Pharma, Inc., a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, finalized their partnership to bring two adjuvant systems to market. The partners will launch these novel adjuvant systems at the
- [Inimmune to present successful Phase I allergy trial results at the American Academy of Allergy Asthma & Immunology meeting in San Diego, February 28-March 3, 2025](https://inimmune.com/inimmune-to-present-successful-phase-i-allergy-trial-results-at-the-american-academy-of-allergy-asthma-immunology-meeting-in-san-diego-february-28-march-3-2025/) - Missoula, MT, February 26, 2025 - Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies for cancer, allergy, autoimmunity, and vaccines will attend the AAAAI meeting in San Diego from February 28-March 3 where Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on Inimmune’s clinical stage treatment for seasonal
- [Inimmune Welcomes Dr. Heather Madsen of Hatteras Venture Partners to Board of Directors](https://inimmune.com/inimmune-welcomes-dr-heather-madsen-of-hatteras-venture-partners-to-board-of-directors/) - Missoula, MT, February 28, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies, is pleased to announce the appointment of Dr. Heather Madsen to its Board of Directors. Dr. Madsen, a distinguished life sciences executive and Operating Partner at Hatteras Venture Partners, brings extensive expertise in the creation of high-performing life science
- [Inimmune To Present On Their Next Generation Adjuvants At World Vaccine Congress in Amsterdam](https://inimmune.com/inimmune-to-present-on-their-next-generation-adjuvants-at-world-vaccine-congress-in-amsterdam/) - Missoula, MT — October 1st, 2025 — Inimmune, a biotechnology company pioneering novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its leadership team will deliver multiple presentations at the World Vaccine Congress (WVC) in Amsterdam, Netherlands, October 13–16, 2025. David Burkhart, Ph.D., CEO of Inimmune, will speak at the Vaccine Delivery Workshop on
- [In silico discovery and mechanistic profiling of STING agonists engaging the transmembrane domain](https://inimmune.com/in-silico-discovery-and-mechanistic-profiling-of-sting-agonists-engaging-the-transmembrane-domain/)
- [Inimmune participates in the development of an innovative intranasal influenza vaccine](https://inimmune.com/inimmune-participates-in-the-development-of-an-innovative-intranasal-influenza-vaccine/) - Inimmune is part of a European consortium, led by the Medical University of Vienna, whose goal is to develop a next-generation vaccine against influenza strains with pandemic potential The consortium aims to be selected under the European Commission’s EU4Health programme Girona, Spain — 24 November 2025 — – Inimmune, a leading clinical stage biotech company
- [Inimmune to Present Trial-in-Progress Poster on First-in-Human Study of INI-4001, a Novel TLR7/8 Agonist, at ASCO 2025](https://inimmune.com/inimmune-to-present-trial-in-progress-poster-on-first-in-human-study-of-ini-4001-a-novel-tlr7-8-agonist-at-asco-2025/) - Missoula, MT, May 29, 2025 – Inimmune Corporation, a clinical-stage biotechnology company focused on developing next-generation immunotherapies, today announced that it will present a Trial-in-Progress poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30–June 3, 2025, in Chicago, IL. The poster, titled "A first-in-human phase 1 clinical trial
- [Inimmune to Present Key Updates at the 2025 World Vaccine Congress in Washington, DC April 21-24](https://inimmune.com/inimmune-to-present-key-updates-at-the-2025-world-vaccine-congress-in-washington-dc-april-21-24/) - Missoula, MT, April 15, 2025 – Inimmune, a clinical-stage biotechnology company specializing in next generation vaccine adjuvants, immunotherapies, and delivery systems, is excited to announce its participation in the 2025 World Vaccine Congress, taking place April 21–24 in Washington, DC. The company will share exciting progress from its clinical-stage immunotherapy and vaccine programs, and take
- [Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization](https://inimmune.com/intranasal-administration-of-a-synthetic-tlr4-agonist-ini-2004-significantly-reduces-allergy-symptoms-following-therapeutic-administration-in-a-murine-model-of-allergic-sensitization-2/)
- [Intranasal administration of a novel synthetic TLR4 agonist suppresses allergen-specific Th2 responses in mice](https://inimmune.com/intranasal-administration-of-a-novel-synthetic-tlr4-agonist-suppresses-allergen-specific-th2-responses-in-mice/)
- [A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models](https://inimmune.com/a-novel-immunostimulatory-tlr7-8-agonist-is-curative-as-a-monotherapy-in-lewis-lung-carcinoma-and-synergizes-with-anti-pd-1-in-b16f10-and-mc38-tumor-models/)
- [Co-delivery of a novel lipidated TLR7/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses](https://inimmune.com/co-delivery-of-a-novel-lipidated-tlr7-8-agonist-and-hemagglutinin-based-influenza-antigen-using-silica-nanoparticles-promotes-enhanced-immune-responses/)
- [Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD](https://inimmune.com/co-delivery-of-novel-synthetic-tlr4-and-tlr7-8-ligands-adsorbed-to-aluminum-salts-promotes-th1-mediated-immunity-against-poorly-immunogenic-sars-cov-2-rbd/)
- [Diamino allose phosphates: Novel, potent, and highly stable Toll-like receptor 4 agonists](https://inimmune.com/diamino-allose-phosphates-novel-potent-and-highly-stable-toll-like-receptor-4-agonists/)
- [Self-adjuvanting TLR7/8 agonist and fentanyl hapten co-conjugate achieves enhanced protection against fentanyl challenge](https://inimmune.com/self-adjuvanting-tlr7-8-agonist-and-fentanyl-hapten-co-conjugate-achieves-enhanced-protection-against-fentanyl-challenge/)
- [Using Dual Toll-like Receptor Agonism to Drive Th1-BiasedResponse in a Squalene- andα-Tocopherol-ContainingEmulsion for a More Effective SARS-CoV-2 Vaccine](https://inimmune.com/using-dual-toll-like-receptor-agonism-to-drive-th1-biasedresponse-in-a-squalene-andα-tocopherol-containingemulsion-for-a-more-effective-sars-cov-2-vaccine/)
- [Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization](https://inimmune.com/intranasal-administration-of-a-synthetic-tlr4-agonist-ini-2004-significantly-reduces-allergy-symptoms-following-therapeutic-administration-in-a-murine-model-of-allergic-sensitization/)
- [Inimmune announces collaboration with UChicago’s Pritzker School of Molecular Engineering (PME) professor Aaron Esser-Kahn to develop novel vaccine adjuvants](https://inimmune.com/inimmune-announces-collaboration-with-uchicagos-pritzker-school-of-molecular-engineering-pme-professor-aaron-esser-kahn-to-develop-novel-vaccine-adjuvants/) - Missoula, MT, October 10, 2023 – With a new NIAID contract, Pritzker Molecular Engineering Prof. Aaron Esser-Kahn will work with UChicago faculty and biotech company Inimmune Inc. to develop a flu vaccine that has fewer side effects for vulnerable populations. READ FULL ARTICLE HERE
- [Inimmune Co-Founder and Chief Scientific and Strategy Officer, Dr. Jay Evans, to be a featured panelist at the 2023 MT Economic Outlook Seminar](https://inimmune.com/inimmune-co-founder-and-chief-scientific-and-strategy-officer-dr-jay-evans-to-be-a-featured-panelist-at-the-2023-mt-economic-outlook-seminar/)
- [Inimmune to Participate at World Vaccine Congress 2023](https://inimmune.com/inimmune-to-participate-at-world-vaccine-congress-2023/)
- [Inimmune to Present an Update on Clinical Stage Programs](https://inimmune.com/inimmune-to-present-an-update-on-clinical-stage-programs/)
- [Inimmune to Participate and Update on Clinical Programs](https://inimmune.com/inimmune-to-participate-and-update-on-clinical-programs/)
- [Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs](https://inimmune.com/inimmune-to-provide-an-update-on-our-vaccine-and-adjuvant-programs/)
- [Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001](https://inimmune.com/inimmune-to-present-on-our-novel-cancer-immunotherapy-ini-4001/)
- [Science Behind the Silent Killer](https://inimmune.com/science-behind-the-silent-killer/) - To passing eyes, the town of Puyallup where Tomi Cook spent her high school years looks the perfect picture of Seattle suburbia. Quiet cookie-cutter houses, rows of shopping centers, happy upper-middle-class families going about their happy lives. She doubts anyone would have suspected that pills were tearing through her community. For Cook it started with
- [UM Receives Largest Single Research Award in its History](https://inimmune.com/um-receives-largest-single-research-award-in-its-history/) - MISSOULA – The National Institutes of Health has awarded the University of Montana a five-year, $33.4 million award for the development and clinical trials of opioid vaccines. It is the largest such award in University history. The award was funded through the NIH HEAL Initiative, a national effort to speed scientific solutions to the national opioid
- [For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set](https://inimmune.com/for-missoulas-inimmune-a-22-m-series-a-round-with-two-bear-capital-is-the-latest-record-set/) - In July 2020, Missoula-based biotech therapeutics company Inimmune Corporation announced the largest Series A investment in Montana history: a $22 million round led by Two Bear Capital out of Whitefish. Founded in 2016, Inimmune develops vaccines and immunotherapeutics in allergy, autoimmunity, infectious disease, opioid addiction and cancer with multiple candidates rapidly advancing to Phase I human clinical trials in
- [Biotech Company Announces $22 Million Investment Led by Mike Goguen’s Firm](https://inimmune.com/biotech-company-announces-22-million-investment-led-by-mike-goguens-firm/) - Inimmune, a Missoula-based biotech company founded by nationally recognized vaccine scientists that has been working on a vaccine for COVID-19, announced today that it has raised $22 million in Series A funding led by Two Bear Capital, a venture-capital firm founded by Whitefish philanthropist Mike Goguen. The firm plans to use the Series A investment
- [Inimmune Welcomes New Chief Medical Officer](https://inimmune.com/inimmune-welcomes-new-chief-medical-officer/) - January 7th, 2022 MISSOULA, Montana, February 2, 2022 – After receiving his medical degree from Loma Linda University and completing an Internal Medicine Residency at Mayo Clinic, Dr. Ruckle served as the founding Medical Director at Northwest Kinetics in Tacoma, WA, from 1995 to 2000. He then led Phase I development at Radiant Research Honolulu
- [Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital](https://inimmune.com/inimmune-raises-22-million-in-series-a-funding-led-by-two-bear-capital/) - MISSOULA, Montana, February 2, 2022 – Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company’s first outside investment. The round was led by Two Bear Capital, www.twobearcapital.com, a new firm based in Whitefish, Montana. Two Bear Capital Founder
- [Inimmune to Play a Key Role at the World Vaccine Congress](https://inimmune.com/inimmune-to-play-a-key-role-at-the-world-vaccine-congress-on-april-3-6-2023/) - MISSOULA, Montana, March 29, 2023 - Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event.Dr. Evans will serve as
- [Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies](https://inimmune.com/montana-biotech-company-receives-2-m-small-business-innovation-research-grant-to-advance-vaccine-technologies/) - MISSOULA, Montana, February 2, 2022 - Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small Business Innovation Research (SBIR) Direct to Phase II program to advance a novel adjuvant and delivery system for vaccines. Adjuvants
- [Inimmune attends BIO International Convention and provides an update on company programs and transition to a clinical stage biotech company.](https://inimmune.com/inimmune-attends-bio-international-convention-and-provides-an-update-on-company-programs-and-transition-to-a-clinical-stage-biotech-company/) - MISSOULA, Montana, June 5, 2023 - Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will provide an update on company programs and clinical trials on May 5th at BIO International Convention in Boston, MA
- [Development of Novel STING Agonists as Vaccine Adjuvants](https://inimmune.com/development-of-novel-sting-agonists-as-vaccine-adjuvants/) - MISSOULA, Montana, March 29, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies, and delivery systems, announced today that its Investigator, Omer Rasheed, Ph.D., will participate and present a poster (P087) at the upcoming ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023 in Boston entitled “Development of Novel STING Agonists as Vaccine Adjuvants”
- [Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004](https://inimmune.com/inimmune-corporation-announces-first-subject-dosed-in-first-in-human-phase-1-clinical-trial-of-its-novel-intranasal-tlr4-agonist-ini-2004-for-the-treatment-of-allergic-rhinitis-and-fda-clearance-of/) - Milestone marks transition of Inimmune Corporation to a clinical-stage company MISSOULA, Montana, August 2, 2023 – Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, today announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential
- [Inimmune Collaborates with Boston Children’s Hospital to Develop Novel Adjuvants](https://inimmune.com/inimmune-collaborates-with-boston-childrens-hospital-to-develop-novel-adjuvants/) - MISSOULA, Montana, October, 24, 2023 – Inimmune Corporation, a clinical-stage biotechnology company focused on creating and developing innovative immunotherapeutics, announced that it has entered a research collaboration with Boston Children's Hospital (BCH) to develop novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a
- [Inimmune’s Chief Scientific and Strategy Officer, Dr. Jay Evans, will participate in BioJapan and provide a company update on clinical programs on Friday, October 13 in Yokohama, Japan](https://inimmune.com/inimmunes-chief-scientific-and-strategy-officer-dr-jay-evans-will-participate-in-biojapan-and-provide-a-company-update-on-clinical-programs-on-friday-october-13-in-yokohama-japan/) - MISSOULA, MT, October 10, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at BioJapan (https://jcd-expo.jp/en/). New immunotherapy drugs and vaccine technologies have shown great promise in the treatment of allergy, cancer,
- [Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6](https://inimmune.com/inimmune-cso-jay-evans-to-present-an-update-on-clinical-stage-programs-at-the-international-precision-vaccine-conference-in-rome-italy-on-october-5-6/) - MISSOULA, Montana, September 26, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will be a speaker at the International Precision Vaccines Conference (https://precisionvaccines2023.com/) in Rome, Italy on October 5-6. The International Precision Vaccine Conference
- [Inimmune to Present on Novel Adjuvants at the 17th Vaccine Congress on September 26th, 2023](https://inimmune.com/inimmune-to-present-on-novel-adjuvants-at-the-17th-vaccine-congress-on-september-26th-2023/) - MISSOULA, MT, September 21, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a plenary presentation at the upcoming 17th Vaccine Congress in Glasgow, Scotland September 24-27th. The event brings together leading
- [UM and Inimmune Receive $12.3 M NIH Contract to Advance New Adjuvant for Vaccines Targeting Bacterial and Fungal Infections](https://inimmune.com/um-and-inimmune-receive-12-3-m-nih-contract-to-advance-new-adjuvant-for-vaccines-targeting-bacterial-and-fungal-infections/) - Contact: Jay Evans, research professor, UM Center for Translational Medicine director, 406-381-0573, jay.evans@umontana.edu. UM Leads $12.3M Contract to Advance TB VaccineUM News Service MISSOULA, Montana, October, 29, 2023 – The National Institutes of Health recently awarded a $12.3 million contract to the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosis
- [Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA](https://inimmune.com/dr-jay-evans-inimmunes-chief-scientific-and-strategy-officer-will-provide-an-update-on-our-innovative-vaccine-and-adjuvant-programs-on-wednesday-december-29-2023-at-the-world-vaccine-con/) - Missoula, MT, November 30, 2023 – Inimmune, a leading clinical stage biotech company focused on thedevelopment of novel vaccines and immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at World Vaccine Congress (West Coast). Innovative vaccine adjuvants and delivery technologies have demonstrated great progress for treatment and
- [Inimmune to present on their Novel Cancer Immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023](https://inimmune.com/inimmune-to-present-on-their-novel-cancer-immunotherapy-ini-4001-at-the-medinvest-oncology-conference-on-december-6th-2023/) - MISSOULA, MT, December 1, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel cancer immunotherapies and vaccine adjuvants and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a presentation at the upcoming MedInvest Oncology Conference in Palo Alto California December 5-6th. The event brings
- [Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy](https://inimmune.com/inimmune-corporation-and-intrommune-therapeutics-announce-a-collaboration-2/) - MISSOULA, Montana, January 8, 2024 - Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its
- [A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice](https://inimmune.com/a-lipidated-tlr7-8-adjuvant-enhances-the-efficacy-of-a-vaccine-against-fentanyl-in-mice/) - S.M. Miller et al.
- [A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models](https://inimmune.com/a-tlr7-8-agonist-increases-efficacy-of-anti-fentanyl-vaccines-in-rodent-and-porcine-models/) - B. Crouse et al.

## Pages

- [Home](https://inimmune.com/) - Harnessing the Immune System to Improve Human Health Our Pipeline Our Pipeline Harnessing the Immune System to Improve Human Health Our Pipeline Our Pipeline Publication June 23, 2026 Characterization of a transmembrane-activating STING agonist using genetically humanized mice Read More Read More Press Releases March 31, 2026 Inimmune to Showcase Pipeline Advances at World Vaccine
- [News](https://inimmune.com/news/) - Latest News The latest in our partnerships, collaborations, company updates, and milestones. March 12, 2026 Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis March 12, 2026 Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis Select Year 2026
- [Sublingual INI-2004: Advancing a New Approach for Food Allergy Immunotherapy[](https://inimmune.com/sublingual-ini-2004-advancing-a-new-approach-for-food-allergy-immunotherapy/) - Sublingual INI-2004: Advancing a New Approach for Food Allergy Immunotherapy Inimmune is advancing a next generation mucosal immunotherapy approach for food allergy, enabled by INI-2004, a next-generation TLR4 agonist, and our proprietary mucoadhesive formulation technology. Through stimulation of TLR4, INI-2004 primes the immune system to mount a Th1-biased, non-allergic response to allergens encountered in the
- [Vaccine Adjuvants](https://inimmune.com/vaccine-adjuvants/) - Innate Immune Agonists as Vaccine Adjuvants Along with reprogramming the immune response to allergies and other inflammatory diseases, innate immune agonists are highly effective at enhancing and directing vaccine-mediated immune responses. Inimmune has developed a number of adjuvants based on innate immune activation and has moved into partnerships to commercialize or distribute these highly effective
- [Cancer Immunotherapy New](https://inimmune.com/cancer-immunotherapy-new/) - INI-4001 Cancer Immunotherapy Every year, cancer claims the lives of more than half a million Americans and is the second leading cause of death in the United States. While checkpoint inhibitors and other novel immunotherapies have resulted in increased life expectancy for some people, current immunotherapies still fail in nearly 80% of cancer patients.Our clinical-stage cancer therapeutic
- [Intranasal INI-2004 for Inhaled Allergies](https://inimmune.com/intranasal-ini-2004-for-inhaled-allergies/) - Intranasal INI-2004 for Inhaled Allergies INI-2004 is uniquely positioned prior to existing gold standard immunotherapies and new competitor entrants. Because of the ease of use of an intranasal product, INI-2004 reduces the reliance on allergen-specific diagnosis and expensive, inconvenient specialist therapies. INI-2004 for Seasonal Allergic Rhinitis Intranasal INI-2004 has been tested in Phase 1 and
- [INI-2004 - A Breakthrough Allergy Immunotherapy](https://inimmune.com/ini-2004-a-breakthrough-allergy-immunotherapy/) - Allergic Disease is a Rapidly Expanding Global Health Problem Allergic disease, including allergic rhinitis, allergic asthma, and food allergies, is one of the most prevalent chronic diseases worldwide. Approximately 10-30% of the global population is affected by allergic rhinitis. That population continues to grow, with the fastest growth seen in industrialized nations. Food allergies are
- [Pipeline](https://inimmune.com/pipeline/) - Our Pipeline: Innate Immune Modulators Inimmune has developed a family of next generation TLR agonists designed for optimal safety, activity, delivery, and stability. Our novel compounds are designed to target specific innate immune pathways to reprogram the immune system and drive a therapeutic response. Our clinical focus is developing INI-2004, a TLR4 agonist, into a
- [Careers](https://inimmune.com/careers/) - Pioneering Innovation Together We are an experienced and close-knit team of industry professionals focused on the discovery and development of disease-modifying immunotherapies. We believe in making meaningful and lasting positive clinical impacts to improve the quality of life for everyone. We are more than just a team. We are ardent scientific pioneers. Working At Inimmune
- [Investors](https://inimmune.com/investors/) - Corporate Overview Inimmune is a clinical-stage innovative biotech company focused on the discovery and development of novel, disruptive immunotherapies for allergy, cancer, infectious and autoimmune diseases. Our deep pipeline of clinical and pre-clinical assets as well as a strong intellectual property position is poised to change the landscape of immunotherapy. Our team has a long
- [About](https://inimmune.com/about/) - Discovery Focused, Development Driven Inimmune’s focus is to discover and develop disease-modifying immunotherapies. Currently, our pipeline includes two clinical-stage Toll-like receptor (TLR) agonists in immuno-oncology and allergy. Both of these TLR agonists generated disease-modifying therapeutic responses in pre-clinical models. Late-stage pre-clinical programs are focused on developing innate immune agonists as next-generation vaccine adjuvants and discovery-stage
- [Advanced Adjuvant Systems](https://inimmune.com/advanced-adjuvant-systems/) - Advanced Adjuvant Systems - Development and Commercialization Next generation adjuvant systems using Inimmune’s novel synthetic TLR4 agonist (INI-2002) We have partnered with SPI Pharma to commercialize two advanced adjuvant systems: T4Q, made up of INI-2002 and QS21, and T4AH, which consists of INI-2002 absorbed to alum. TLR4 agonists are well established to synergize with other
- [Privacy Policy](https://inimmune.com/privacy-policy/) - Please wait while the policy is loaded. If it does not load, please click here to view the policy.
- [Cancer Immunotherapy](https://inimmune.com/cancer-immunotherapy/) - Cancer Immunotherapy For ongoing clinical trial information: NCT06302426 Every year, cancer claims the lives of more than half a million Americans and is the second leading cause of death in the United States. While checkpoint inhibitors and other novel immunotherapies have resulted in increased life expectancy for some people, current immunotherapies still fail in nearly
- [Allergy Immunotherapy](https://inimmune.com/allergy-immunotherapy/) - Allergy Immunotherapy For ongoing clinical trial information: NCT06038279 At Inimmune, we’re developing a rapid disease-modifying treatment for allergies which does not require identification of the allergen. In the US, nearly 1 in 3 adults and more than 1 in 4 children report having a seasonal allergy, eczema, or food allergy. Worldwide, an estimated 220 million
- [Leadership](https://inimmune.com/leadership/) - Management Team David Burkhart, Ph.D. Chief Executive Officer Shannon Miller, Ph.D. VP, Operations Jay Evans, Ph.D. Chief Scientific & Strategy Officer Helene Bazin-Lee, Ph.D. VP, Discovery Ryan McMillian Head of Financial Strategy Ferdinand E. Massari, M.D. Chief Medical Officer Kendal Ryter, Ph.D. VP, Manufacturing & Dev. Joseph Sulovski VP, Clinical Operations Michael Conger, J.D. VP,
- [TRAC478 Vaccine Adjuvant](https://inimmune.com/trac478-vaccine-adjuvant/) - TRAC478 Vaccine Adjuvant A new combination adjuvant approach TRAC478 is a new combination adjuvant approach in which INI-2002, a TLR4 adjuvant, and INI-4001, a TLR7/8 adjuvant are used together to generate synergistic immune responses. Pre-clinically, TRAC478 results in strong Th1-biased antibody and T cell responses and is efficacious in influenza challenge models. TRAC478 can be
- [Opioid Vaccine](https://inimmune.com/opioid-vaccine/) - Opioid Vaccine From 1999 to today, more than one million people have died from a drug overdose. Tragically, from 1999 to today, more than one million people have died from a drug overdose. Opioids, particularly synthetic opioids such as fentanyl, are involved in the majority of drug overdose deaths. INI-4001 Adjuvanted Opioid Vaccine Deaths among
- [Contact](https://inimmune.com/contact/) - Contact Us Please contact us with any inquiries. Name Email Reason For Contact Select a Reason Collaborations and Partnerships Careers Investment Opportunities Media & Press Other Subject Message You agree to our friendlyprivacy policy. Send Message Office 1121 E Broadway St, Ste 106, Missoula, MT, 59802 Email info@inimmune.com Phone (406) 541-5913
- [Terms of Service](https://inimmune.com/terms-of-service/) - Please wait while the policy is loaded. If it does not load, please click here.
- [Publications](https://inimmune.com/publications/) - Publications & Posters Publications Posters Publications Cell Reports | June 23, 2026 Characterization of a transmembrane-activating STING agonist using genetically humanized mice Read More European Journal of Medicinal Chemistry | September 27, 2025 In silico discovery and mechanistic profiling of STING agonists engaging the transmembrane domain Read More NPJ Viruses | August 6, 2024 Vaccination
- [INI-1098 Vaccine Adjuvant](https://inimmune.com/ini-1098-vaccine-adjuvant/) - INI-1098 Vaccine Adjuvant A novel synthetic Mincle agonist INI-1098 is a novel synthetic Mincle agonist that is being developed as a Th17-generating adjuvant for bacterial and fungal pathogens. Mincle is a C-type lectin receptor (CLR) that was originally discovered as the ligand for the Mycobacterium tuberculosis (Mtb) cell wall component trehalose dimycolate (TDM). Th17 cells
- [Style Guide](https://inimmune.com/style-guide/) - Apply the global style for this project and then remove this page from the settings as home page. Red #E11837 Yellow #FFFA99 Green #00A651 Titles #201211 Body #4B5563 Captions #757575 Button Text Button Text Click here Click here Click here Click here Click here Click here Click here Click here Click here Click here Click

## Mega Menu Items

- [elementor-mega-item-4352](https://inimmune.com/jet-menu/elementor-mega-item-4352/)
- [elementor-mega-item-446](https://inimmune.com/jet-menu/elementor-mega-item-446/) - Allergy Immunotherapy Cancer Immunotherapy Opioid Vaccine Advanced Adjuvant Systems TRAC478 Vaccine Adjuvant INI-1098 Vaccine Adjuvant Allergy Immunotherapy Cancer Immunotherapy Opioid Vaccine Advanced Adjuvant Systems TRAC478 Vaccine Adjuvant INI-1098 Vaccine Adjuvant
- [elementor-mega-item-441](https://inimmune.com/jet-menu/elementor-mega-item-441/) - Leadership Publications Leadership Publications
- [elementor-mega-item-123](https://inimmune.com/jet-menu/elementor-mega-item-123/)
- [default-mega-item-123](https://inimmune.com/jet-menu/default-mega-item-123/)

## JetPopup

- [Team Popup New](https://inimmune.com/jet-popup/team-popup-new/) - Team Popup New

## Team Member

- [Shannon Miller, Ph.D.](https://inimmune.com/team-member/shannon-miller/) - Dr. Shannon Miller is the Vice President of Operations at Inimmune, where she also leads the company's immunology R&D team. Prior to serving as VP of Operations, Dr. Miller previously served as an Investigator and Director at Inimmune and held a faculty position at the University of Montana. Dr. Miller earned her PhD in Immunology
- [Ryan McMillian](https://inimmune.com/team-member/ryan-mcmillian/) - Ryan McMillian is a strategic finance leader and fractional Chief Financial Officer who partners with venture-backed biotech companies as they scale clinical portfolios, prepare for major financings, and evaluate strategic transactions. He works closely with founders, scientific leadership, and boards to align development strategy, capital planning, and investor messaging as organizations move from early clinical
- [Ferdinand E. Massari, M.D.](https://inimmune.com/team-member/ferdinand-e-massari-m-d/) - Ferdinand (Ferd) Massari, M.D., is an accomplished biopharmaceutical executive with a proven record of building and leading high-performing organizations that consistently exceed expectations. Over his career, Ferd has played a pivotal role in the approval of multiple therapies that have improved millions of lives worldwide. His leadership spans the full biopharma value chain, with executive
- [Helene Bazin-Lee, Ph.D.](https://inimmune.com/team-member/helene-bazin-lee-ph-d/) - Dr. Bazin-Lee is VP, Early Discovery and Co-Founder of Inimmune, serving as head of early discovery research programs. She has over 17 years of experience in the biotech and pharmaceutical industries including 14 years with Corixa/GlaxoSmithKline developing new synthetic immunomodulators and vaccine adjuvants, managing medicinal chemistry efforts and new adjuvant discovery projects. Dr. Bazin-Lee earned
- [Jon Ruckle, M.D.](https://inimmune.com/team-member/chief-financial-officer/) - Dr. Ruckle brings over 25 years of clinical trial experience including protocol design, product development strategy, and medical monitoring. He has served as an Investigator for over 350 clinical trials. Dr. Ruckle will oversee the global clinical development and regulatory activites for Inimmune. After receiving his medical degree from Loma Linda University and completing an
- [Mike Sullivan, CPA](https://inimmune.com/team-member/mike-sullivan-cpa/) - Mr. Sullivan is serving as our Chief Financial Officer since December 12, 2022. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including First Advantage Corporation, Utek Corporation, eANGLER, and HSN Direct International Limited. Most recently, he was the Chief Financial Officer for Oragenics Inc. Oragenics is a development-stage
- [Edwin Kim, MD MS](https://inimmune.com/team-member/edwin-kim-md-ms/) - Edwin Kim is an Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine. In 2015, he was named Director of the UNC Food Allergy Initiative, and he has led over 40 PI-initiated, NIH multi-center, and industry-sponsored clinical trials. He is PI
- [David Burkhart, Ph.D.](https://inimmune.com/team-member/david-burkhart-ph-d/) - Dr. David Burkhart is the Chief Executive Officer and a Co-Founder of Inimmune. A passionate, direct and results oriented team leader, he strives to bring out the best in people by inspiring them to realize their untapped potential. Dr. Burkhart brings nearly 20 years of experience in the biotechnology and pharmaceutical industries with proficiencies in
- [Michael Conger, J.D.](https://inimmune.com/team-member/michael-conger-j-d/) - Before joining Inimmune, Mr. Conger served as Assistant General Counsel-Patents for GlaxoSmithKline (GSK), advising leaders of research programs for fourteen years, including a close association with the scientists who would later found Inimmune. Prior to GSK, Mr. Conger worked five years in private practice at a large, regional firm in Salt Lake City. Mr. Conger
- [Kendal Ryter, Ph.D.](https://inimmune.com/team-member/kendal-ryter-ph-d/) - Dr. Ryter is VP, Manufacturing and Development and Co-Founder of Inimmune. He started his postgraduate synthetic career working at Albany Molecular Research, Inc. In Albany NY. The experience highlighted his ability to adapt and come up to speed quickly on new projects and classes of drug pharmacophores. From alkaloids to opiates to complex heterocycles he
- [Joseph Sulovski](https://inimmune.com/team-member/lucy-tennant-m-s/) - Joe Sulovski serves as the Vice President of Clinical Operations at Inimmune Corporation, bringing over 20 years of leadership experience in clinical research across oncology, immunology, and vaccine therapeutics. His career is distinguished by a focus on advancing innovative clinical development strategies and aligning operational priorities with organizational goals. At Inimmune, Joe plays a pivotal
- [Jay Evans, Ph.D.](https://inimmune.com/team-member/jay-evans-ph-d/) - Dr. Evans is the Chief Scientific and Strategy Officer and Cofounder of Inimmune Corp. Dr. Evans is also Director of the Center for Translational Medicine at the University of Montana and a Research Professor in the Division of Biological Sciences. He has over 20 years’ experience in the biotechnology and pharmaceutical industry including 15 years
- [Heather Madsen, Ph.D.](https://inimmune.com/team-member/heather-madsen/) - Heather Madsen holds a PhD in Evolutionary Genetics and joined the pharmaceutical industry in 2001. During her 22-year career at GSK and ViiV Healthcare, Heather held a variety of leadership roles including Head of R&D for the European Pharma Diagnostics Business Unit, Senior Director of Target Sciences Infectious Disease, and Executive Director of Research for
- [James Allison, Ph.D.](https://inimmune.com/team-member/james-allison-ph-d/) - Dr. James Allison is the Regental Chair and Professor of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair of Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of
- [Padmanee Sharma, M.D., Ph.D.](https://inimmune.com/team-member/padmanee-sharma-m-d-ph-d/) - Dr. Sharma is a nationally and internationally renowned physician-scientist whose research work is focused on investigating immunologic mechanisms and pathways that impact tumor rejection. She is a trained medical oncologist and immunologist and the T.C. and Jeanette D. Hsu Endowed Chair in Cell Biology. Her expertise in Immunology and Genitourinary Medical Oncology enabled her to
- [Jean-Paul Prieels, Ph.D.](https://inimmune.com/team-member/jean-paul-prieels-ph-d/) - Jean-Paul Prieels holds a Ph.D. in biochemistry from Université Libre de Bruxelles in Belgium. He started his industrial career at Petrofina in 1983 as a biotechnology manager and joined GSK Vaccines in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities as Senior Vice President of Research and Development at GlaxoSmithKline
- [Thomas Casale, M.D.](https://inimmune.com/team-member/thomas-casale-m-d/) - Dr. Casale joined the Division of Allergy/Immunology in 2013 as Professor of Medicine and Pediatrics and Chief of Clinical and Translational Research. He is also Chief Medical Advisor, Food Allergy Research and Education (FARE). Prior, he was Professor of Medicine and Medical Microbiology and Immunology and Chief of Allergy/Immunology at Creighton University. He did an
- [Michael Goguen](https://inimmune.com/team-member/michael-goguen/) - Michael Goguen is the founder and managing partner of Two Bear Capital, a venture capital firm in Whitefish, Montana, Boston, San Diego, and the San Francisco Bay area that invests in companies at the intersection of biotechnology, bioinformatics, artificial intelligence/machine learning and cybersecurity. Previously, Mike was a partner at Sequoia Capital where he proved his

## Careers

- [Medical Chemistry Intern](https://inimmune.com/careers/medical-chemistry-intern/)

## Categories

- [Press Releases](https://inimmune.com/category/press-releases/)
- [Articles](https://inimmune.com/category/articles/)
- [Events](https://inimmune.com/category/events/)
- [Publication](https://inimmune.com/category/publication/)
- [Poster](https://inimmune.com/category/poster/)

## Tags

- [Featured](https://inimmune.com/tag/featured/)

## Publication Year

- [2024](https://inimmune.com/publication-year/2024/)
- [2023](https://inimmune.com/publication-year/2023/)
- [2022](https://inimmune.com/publication-year/2022/)
- [2020](https://inimmune.com/publication-year/2020/)
- [2019](https://inimmune.com/publication-year/2019/)
- [2025](https://inimmune.com/publication-year/2025/)
- [2026](https://inimmune.com/publication-year/2026/)

## Team Category

- [Management Team](https://inimmune.com/team-category/management-team/)
- [Board of Directors](https://inimmune.com/team-category/board-of-directors/)
- [Scientific Advisory Board](https://inimmune.com/team-category/scientific-advisory-board/)